Detail akcie BioXcel Therptc Rg online

Business Summary: BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2026, BioXcel Therapeutics Inc revenues increased 23% to $206K. Net loss increased 75% to $12.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 1% to $10.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.50 to -$0.54.